MethodĪ 3-week prospective study was performed with 12 patients comparing capillary and interstitial glucose during dialysis. Of the CGMs, FreeStyle Libre ® is the most used in worldwide, but there is still no consensus on its use in dialysis. This study confirms the radical improvements Flash can bring to the lives of people living with type 1 diabetes, helping them to reduce their blood glucose levels – protecting against short and long-term diabetes complications – and removing some of the relentless burden of managing the condition.īy demonstrating the benefits to people living with type 1 diabetes and the value for money to the NHS – which currently spends 10 per cent of its budget on diabetes care – we hope these results encourage healthcare professionals and people with type 1 diabetes to consider flash glucose monitoring as a cost-effective and life-improving intervention.Studies highlight the inaccuracy of glycated hemoglobin (HbA1c) for the assessment of glycemic control in dialysis diabetics and suggest the use of continuous glucose monitoring (CGM) as an alternative. While Flash was found to be slightly more expensive than finger-prick testing over a patient’s lifetime, the team predicted that the device would help keep patients healthier for longer – thereby reducing complications and NHS costs to treat these.ĭr Elizabeth Robertson, Director of Research at Diabetes UK, which funded the study, added: “We want as many people as possible to have access to innovative diabetes technologies. Researchers also assessed the long-term cost effectiveness of the two monitoring approaches. We call for universal funding of this life changing technology for all people living with type 1 diabetes. This intervention was highly cost-effective and led to high level of treatment satisfaction. With the use of second-generation Flash technology, we found significant improvements in average glucose levels and a reduction in both high and low glucose levels, helping people to spend more time with normal glucose levels thereby reducing their risk of long-term diabetes related complications. “The ability to monitor glucose without painful finger-sticks is life-changing for many people living with type 1 diabetes. economic analysis by Professor Rachel Elliott (Professor of Health Economics, UoM) found that that FreeStyle Libre 2 is likely to be highly cost-effective.ĭr Lalantha Leelarathna, who is also an Honorary Senior Lecturer at UoM, recently shared the findings at the Diabetes UK Professional Conference.Professor Katharine Barnard’s ( Barnard Health) work on patient reported outcomes showed that participants using Freestyle Libre 2 were happier with their diabetes treatment and that using the technology reduced the day-to-day burden and emotional strain of living with their condition. these patients also spent an extra two hours a day with their blood glucose levels in the target range and 80 per cent less time with dangerously low blood glucose levels.patients using Flash monitoring showed improved blood glucose levels closer to the target range, reducing their risk of serious short and long-term complications.Participants were then randomly allocated into two groups – one using the Freestyle Libre 2 Flash device to monitor their glucose levels and the other continuing to use finger-prick testing. All participants had glucose levels above the target range for avoiding long term complications. With MFT acting as lead centre, 156 adult patients with type 1 diabetes were recruited from MRI and other trusts across the United Kingdom between January 2020 and September 2021. Researchers also looked at how this affected patient’s quality of life, and whether Flash was cost-effective for use on the NHS. The research looked at whether second-generation Flash technology was better than finger-prick testing in helping patients to better manage their condition and keep blood sugar levels within the target range to avoid complications. MRI Diabetes Research Team L-R: Mini Karuppan (Senior Clinical Research Nurse), Jose Rubio (Senior Clinical Research Nurse), Dr Lalantha Leelarathna (Consultant Diabetologist), Majid Nazir (Senior Clinical Trials Coordinator), Womba Mubita (Nurse Manager), Dr Hood Thabit (Consultant Diabetologist). Biobank and Cellular Pathology Research Service.Clinical Photography and Medical Illustration.NIHR Manchester Biomedical Research Centre.NIHR Manchester Clinical Research Facility.NIHR Centre for Precision Approaches to Combatting Antimicrobial Resistance.Intellectual Property (IP) and Innovation Management Service.University Dental Hospital of Manchester.
0 Comments
Leave a Reply. |